Maxnerva Technology Services 미래 성장

Future 기준 확인 0/6

현재 Maxnerva Technology Services 의 성장과 수익을 예측할 만큼 분석가의 범위가 충분하지 않습니다.

주요 정보

n/a

수익 성장률

n/a

EPS 성장률

IT 수익 성장	13.7%
매출 성장률	n/a
향후 자기자본 수익률	n/a
애널리스트 커버리지	None
마지막 업데이트	n/a

최근 미래 성장 업데이트

Recent updates

Maxnerva Technology Services Limited (HKG:1037) Stock Catapults 32% Though Its Price And Business Still Lag The Industry

Sep 10

Maxnerva Technology Services Limited (HKG:1037) Surges 33% Yet Its Low P/S Is No Reason For Excitement

Apr 10

Maxnerva Technology Services Limited's (HKG:1037) Share Price Boosted 29% But Its Business Prospects Need A Lift Too

Feb 21

Maxnerva Technology Services Limited's (HKG:1037) Share Price Is Matching Sentiment Around Its Earnings

Dec 30

Here's What's Concerning About Maxnerva Technology Services' (HKG:1037) Returns On Capital

Oct 12

There Are Reasons To Feel Uneasy About Maxnerva Technology Services' (HKG:1037) Returns On Capital

Jun 29

Maxnerva Technology Services' (HKG:1037) Returns On Capital Not Reflecting Well On The Business

Dec 26

Maxnerva Technology Services (HKG:1037) Is Reinvesting At Lower Rates Of Return

Sep 27

Maxnerva Technology Services' (HKG:1037) Returns On Capital Are Heading Higher

Mar 18

Maxnerva Technology Services (HKG:1037) Is Experiencing Growth In Returns On Capital

Dec 03

Maxnerva Technology Services (HKG:1037) Shareholders Will Want The ROCE Trajectory To Continue

Jul 26

Calculating The Intrinsic Value Of Maxnerva Technology Services Limited (HKG:1037)

May 11

Returns Are Gaining Momentum At Maxnerva Technology Services (HKG:1037)

Apr 06

How Much Did Maxnerva Technology Services'(HKG:1037) Shareholders Earn From Share Price Movements Over The Last Five Years?

Mar 02

Here's Why Maxnerva Technology Services' (HKG:1037) Statutory Earnings Are Arguably Too Conservative

Feb 04

Maxnerva Technology Services Limited's (HKG:1037) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Jan 14

Is There More Growth In Store For Maxnerva Technology Services' (HKG:1037) Returns On Capital?

Dec 16

이 섹션에서는 일반적으로 투자자가 회사의 수익 창출 능력을 이해하는 데 도움이 되도록 전문 애널리스트의 컨센서스 추정치를 기반으로 수익 및 수익 성장 전망치를 제시합니다. 하지만 Maxnerva Technology Services 은 충분한 과거 데이터를 제공하지 않았고 애널리스트 예측도 없기 때문에 과거 데이터를 추정하거나 애널리스트 예측을 사용하여 미래 수익을 안정적으로 계산할 수 없습니다.

SimplyWall St에서 다루는 기업의 97%가 과거 재무 데이터를 가지고 있기 때문에 이는 매우 드문 상황입니다.

수익 및 매출 성장 예측

SEHK:1037 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (CNY Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
6/30/2024	583	-39	55	56	N/A
3/31/2024	630	-28	43	44	N/A
12/31/2023	678	-17	31	33	N/A
9/30/2023	753	5	20	21	N/A
6/30/2023	827	27	9	10	N/A
3/31/2023	830	28	14	16	N/A
12/31/2022	832	28	20	22	N/A
9/30/2022	765	28	23	26	N/A
6/30/2022	697	29	25	29	N/A
3/31/2022	647	32	18	22	N/A
12/31/2021	596	34	11	15	N/A
9/30/2021	560	25	-10	-10	N/A
6/30/2021	524	16	-31	-35	N/A
3/31/2021	524	16	10	9	N/A
12/31/2020	523	15	51	53	N/A
9/30/2020	530	15	N/A	N/A	N/A
6/30/2020	536	15	87	97	N/A
3/31/2020	483	13	81	89	N/A
12/31/2019	431	12	75	81	N/A
9/30/2019	402	20	N/A	N/A	N/A
6/30/2019	374	28	6	12	N/A
3/31/2019	350	14	-11	-6	N/A
12/31/2018	326	1	-27	-24	N/A
12/31/2017	447	57	N/A	-29	N/A
9/30/2017	328	79	N/A	48	N/A
6/30/2017	334	85	N/A	44	N/A
3/31/2017	345	92	N/A	40	N/A
12/31/2016	361	22	N/A	N/A	N/A
9/30/2016	262	-23	N/A	-29	N/A
6/30/2016	178	-43	N/A	-39	N/A
3/31/2016	93	-61	N/A	-47	N/A
12/31/2015	93	-29	N/A	N/A	N/A
9/30/2015	92	3	N/A	-26	N/A
6/30/2015	97	3	N/A	-32	N/A
3/31/2015	104	3	N/A	-38	N/A
9/30/2014	292	4	N/A	-23	N/A
6/30/2014	396	4	N/A	-11	N/A
3/31/2014	496	4	N/A	2	N/A

애널리스트 미래 성장 예측

수입 대 저축률: 1037 의 예상 수익 증가율이 절약률( 2.3% )보다 높은지 판단하기에는 데이터가 부족합니다.

수익 vs 시장: 1037 의 수익이 Hong Kong 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: 1037 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

수익 대 시장: 1037 의 수익이 Hong Kong 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: 1037 의 수익이 연간 20% 보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: 1037 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Maxnerva Technology Services 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Maxnerva Technology Services Limited Provides Earnings Guidance for the Six Months Ended 30 June 2022

Recent updates

New minor risk - Share price stability

Maxnerva Technology Services Limited (HKG:1037) Stock Catapults 32% Though Its Price And Business Still Lag The Industry

First half 2024 earnings released: CN¥0.023 loss per share (vs CN¥0.008 profit in 1H 2023)

New major risk - Revenue and earnings growth

Maxnerva Technology Services Limited Announces Directorate Changes

Maxnerva Technology Services Limited to Report Q2, 2024 Results on Aug 21, 2024

Now 21% undervalued

Maxnerva Technology Services Limited, Annual General Meeting, May 24, 2024

New major risk - Share price stability

Now 27% undervalued

Maxnerva Technology Services Limited (HKG:1037) Surges 33% Yet Its Low P/S Is No Reason For Excitement

Full year 2023 earnings released: CN¥0.024 loss per share (vs CN¥0.04 profit in FY 2022)

Maxnerva Technology Services Limited Announces Chief Executive Officer Changes

Maxnerva Technology Services Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Maxnerva Technology Services Limited's (HKG:1037) Share Price Boosted 29% But Its Business Prospects Need A Lift Too

Maxnerva Technology Services Limited's (HKG:1037) Share Price Is Matching Sentiment Around Its Earnings

Here's What's Concerning About Maxnerva Technology Services' (HKG:1037) Returns On Capital

Maxnerva Technology Services Limited Announces Board Changes

First half 2023 earnings released: EPS: CN¥0.008 (vs CN¥0.009 in 1H 2022)

Maxnerva Technology Services Limited to Report First Half, 2023 Results on Aug 28, 2023

There Are Reasons To Feel Uneasy About Maxnerva Technology Services' (HKG:1037) Returns On Capital

Full year 2022 earnings released: EPS: CN¥0.04 (vs CN¥0.05 in FY 2021)

Maxnerva Technology Services' (HKG:1037) Returns On Capital Not Reflecting Well On The Business

Less than half of directors are independent

First half 2022 earnings released: EPS: CN¥0.009 (vs CN¥0.017 in 1H 2021)

Maxnerva Technology Services (HKG:1037) Is Reinvesting At Lower Rates Of Return

First half 2022 earnings released: EPS: CN¥0.009 (vs CN¥0.017 in 1H 2021)

Maxnerva Technology Services Limited Provides Earnings Guidance for the Six Months Ended 30 June 2022

Maxnerva Technology Services Limited to Report Q2, 2022 Results on Aug 26, 2022

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥0.05 (vs CN¥0.022 in FY 2020)

Maxnerva Technology Services' (HKG:1037) Returns On Capital Are Heading Higher

Maxnerva Technology Services (HKG:1037) Is Experiencing Growth In Returns On Capital

First half 2021 earnings released: EPS CN¥0.017 (vs CN¥0.015 in 1H 2020)

First half 2021 earnings released: EPS CN¥0.017 (vs CN¥0.015 in 1H 2020)

Maxnerva Technology Services (HKG:1037) Shareholders Will Want The ROCE Trajectory To Continue

Calculating The Intrinsic Value Of Maxnerva Technology Services Limited (HKG:1037)

Non-Executive Director has left the company

Returns Are Gaining Momentum At Maxnerva Technology Services (HKG:1037)

Full year 2020 earnings released: EPS CN¥0.022 (vs CN¥0.018 in FY 2019)

Maxnerva Technology Services Limited to Report Fiscal Year 2020 Results on Mar 31, 2021

How Much Did Maxnerva Technology Services'(HKG:1037) Shareholders Earn From Share Price Movements Over The Last Five Years?

New 90-day high: HK$0.90

Here's Why Maxnerva Technology Services' (HKG:1037) Statutory Earnings Are Arguably Too Conservative

Maxnerva Technology Services Limited's (HKG:1037) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

New 90-day high: HK$0.65

Is There More Growth In Store For Maxnerva Technology Services' (HKG:1037) Returns On Capital?

New 90-day high: HK$0.47

First half earnings released

New 90-day high - HK$0.34

Earnings released

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견